C-Path Global Impact Conference 2025: Call to action from day two: Look to the future of PPPs

Описание: This discussion from Critical Path Institute’s Global Impact Conference (CGIC) 2025 offers a comprehensive exploration of the evolving role of public-private partnerships (PPPs) in advancing early disease interception, particularly in complex fields like Parkinson’s disease and rare diseases. The conversation, led by C-Path Executive Director of its Translational Therapeutics Accelerator (TRxA) Maaike Everts, C-Path Senior Scientific Director Martijn Müller, Maryland Innovation Initiative Executive Director Abi Kulshreshtha, and Reagan-Udall Foundation CEO Susan Winckler, highlights the critical need for collaboration, trust, and shared learning among stakeholders—including regulators, industry, academia, patients, and state organizations—to accelerate innovation while addressing systemic challenges.

Using Parkinson’s disease as a case study, the panelists discuss biomarker development, the integration of digital health technologies (DHTs), and the potential of novel approaches to methodologies (NAMs), including non-animal models and AI, in revolutionizing drug development and regulatory science.

Key Insights

Early Disease Intervention Requires Sensitive Biomarkers: Parkinson’s disease exemplifies the challenge and opportunity in early intervention, where symptoms are subtle or absent.

Multistakeholder Collaboration Is Essential for Effective Frameworks: Developing disease staging frameworks or regulatory tools in isolation risks narrow applicability.

State Governments as Catalysts in Translational Research: States hold unique financial resources, longitudinal health data, and are on the front lines of healthcare delivery.

Global Regulatory Harmonization Through Shared Learning: The panel reveals that harmonizing regulatory standards globally is not simply a matter of aligning rules but requires ongoing dialogue and mutual learning among regulators at various levels.

Digital Health Technologies (DHTs) Enhance Measurement Precision but Bring Complexity: Continuous monitoring via wearable devices offers rich, real-world data that can capture disease heterogeneity and fluctuations.

Bidirectional Education and Trust Building Through PPPs: These partnerships serve as platforms where patients, clinicians, regulators, and industry educate each other about needs, concerns, and practical realities.

Effective PPPs Require Clear Governance, Scope Management, and Honest Reflection: Panelists emphasize that success depends on well-defined goals, agile leadership, and the discipline to say no to scope creep

SUBSCRIBE to C-Path's YouTube Channel Now ►►    / criticalpathinstitute  

FOLLOW C-Path:
►LinkedIn:   / c-path  
►Facebook:   / cpathinstitute  
►X: https://twitter.com/CPathInstitute?re
►Instagram:   / cpathinstitute  


About Critical Path Institute C-Path is an independent, nonprofit established in 2005 as a public-private partnership, in response to the FDA’s Critical Path Initiative. C-Path’s mission is to lead collaborations that advance better treatments for people worldwide. Globally recognized as a pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives that currently include more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotech companies. With dedicated team members located throughout the world, C-Path’s global headquarters is located in Tucson, Arizona and C-Path’s Europe subsidiary is headquartered in Amsterdam, Netherlands. For more information, visit c-path.org. #CPath #drugdiscovery #researchgrants #globalhealth #drugdevelopment #datasharing #researchfunding #raredisease #academicresearch #regulatoryscience #globalhealth #consortia #collaboration #FDA #EMA #T1D #Parkinsons #Alzheimers #PKD #Duchenne #ALS #biomarkers